tiprankstipranks
Advertisement
Advertisement
Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained
PremiumRatingsCaribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained
1M ago
Caribou Biosciences presents ANTLER trial results at EHA
Premium
The Fly
Caribou Biosciences presents ANTLER trial results at EHA
1M ago
Caribou Biosciences Highlights Strong Allogeneic CAR-T Trial Results
Premium
Company Announcements
Caribou Biosciences Highlights Strong Allogeneic CAR-T Trial Results
1M ago
Caribou Biosciences price target raised to $13 from $11 at Evercore ISI
PremiumThe FlyCaribou Biosciences price target raised to $13 from $11 at Evercore ISI
5M ago
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
Premium
Ratings
Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating
5M ago
Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access
Premium
Company Announcements
Drug Pricing Reforms Threaten Caribou Biosciences’ Future Margins and Market Access
5M ago
Caribou Biosciences: Promising Financials and Clinical Success Drive Buy Rating
PremiumRatingsCaribou Biosciences: Promising Financials and Clinical Success Drive Buy Rating
8M ago
Caribou Biosciences Reports Increased Losses Amid R&D Focus
Premium
Company Announcements
Caribou Biosciences Reports Increased Losses Amid R&D Focus
8M ago
Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year
Premium
The Fly
Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100